Document is current
Any future updates will be listed below
-
Authors
Zhang, Yongchang
Zhang, Xiangyu
Zhang, Ruiguang
Xu, Qinqin
Yang, Haiyan
Lizaso, Analyn
Xu, Chunwei
Liu, Jun
Wang, Wenxian
Ou, Sai-Hong Ignatius
Zhang, Jiexia
Song, Zhengbo
Yang, Nong
-
Funding
Funding for this research was provided by:
Natural Science Foundation of Hunan Province (2020SK2031, 2020SK2030, 2018RS3106, 2019-TJ-N04, kq1801102, 2019SK4010, and 2020JJ3025)
- License Information
-
More Information
Article History
Received: 27 May 2021
Accepted: 2 August 2021
First Online: 13 September 2021
Declarations
:
: Approval of the study protocol was obtained from the Hunan Cancer Hospital Institutional Review Board Committee (approval number: 2017YYQ-SSB-026). All patients provided written informed consent for the use of their clinical and molecular data for research purposes.
: Not applicable
: Analyn Lizaso declared that she is employed by Burning Rock Biotech. Sai-Hong Ignatius Ou has stock ownership and was on the scientific advisory board of Turning Point Therapeutics Inc (until Feb 28, 2019), is a member of the SAB of Elevation Oncology and has stock ownership in Elevation Oncology, and has received speaker honorarium from Merck, Roche/Genentech, Astra Zeneca, Takeda/ARIAD and Pfizer; has received advisory fees from Roche/Genentech, Astra Zeneca, Takeda/ARIAD, Pfizer, Foundation Medicine Inc, Spectrum, Daiichi Sankyo, Jassen/JNJ, and X-Covery. All the other authors declare no conflict of interest.
